Actavis Must Face Warning, Design Defect Claims in Testosterone Replacement MDL Case

  • Order

CHICAGO — An Illinois federal judge has denied Actavis Inc. summary judgment on claims for failure to warn and design defect in a testosterone replacement therapy MDL case, ruling there is a question of fact as to whether their prescribing doctor would have acted differently had he been presented with a different warning.

In a Nov. 1 order, Judge Matthew Kennelly of the U.S. District Court for the Northern District of Illinois also denied the parties’ motions to exclude expert testimony, ruling the experts were qualified to render their opinions and that they were backed by sound methodology.

Florida resident …


HarrisMartin’s Benzene and Toxic Tort Litigation Conference: Recent Developments and Future Trends

December 01, 2023 - Charleston, SC
The Charleston Place


HarrisMartin's New Jersey Asbestos Litigation Conference

March 01, 2024 - New Brunswick, NJ
Hyatt Regency New Brunswick